The Global Carotid Artery Stent Market, valued at USD 621.4 Million in 2025, is projected to exhibit a CAGR of 4.0%, reaching USD 817.7 Million by 2032.
Market growth is driven by the rising prevalence of carotid artery stenosis and related cerebrovascular diseases, increasing adoption of minimally invasive endovascular procedures, and growing awareness of stroke prevention strategies. Advancements in stent designs, such as next-generation self-expanding and drug-eluting stents, alongside improvements in embolic protection devices, are enhancing procedural safety and efficacy, thereby supporting the market expansion.
Additionally, growing geriatric population at higher risk of atherosclerosis, expanding healthcare infrastructure in emerging economies, and supportive reimbursement policies for carotid interventions are anticipated to further drive demand for carotid artery stents over the forecast period.
Market Takeaways
Global Carotid Artery Stent Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/carotid-artery-stent-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 621.4 Million |
|
Estimated Value by 2032 |
USD 817.7 Million |
|
Growth Rate |
Poised to exhibit a CAGR of 4.0% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The global carotid artery stent market is experiencing steady growth, driven by the rising prevalence of carotid artery stenosis and related cerebrovascular disorders, coupled with the increasing adoption of minimally invasive endovascular procedures. Growing awareness of stroke prevention, supported by improved diagnostic screening programs and expanding access to vascular interventions, is fueling demand. Hospitals and clinics remain the primary end users due to their advanced infrastructure, availability of specialized vascular surgeons, and ability to handle complex carotid revascularization procedures, while ambulatory surgical centers are increasingly contributing to the market as outpatient interventions gain traction.
Technological advancements are transforming the market landscape, with the development of next-generation self-expanding and balloon-expandable stents, as well as drug-eluting, bioabsorbable, and biodegradable stents that reduce restenosis risk and improve long-term outcomes. Integration of advanced embolic protection devices and imaging-guided navigation systems is enhancing procedural safety and efficacy, supporting the broader adoption of stenting over traditional carotid endarterectomy. Moreover, continuous research and innovation are focusing on improving stent biocompatibility, flexibility, and delivery systems to cater to diverse patient needs.
Despite the positive outlook, the market faces challenges such as the high cost of carotid stenting procedures, limited reimbursement in certain developing regions, and the availability of alternative treatments like carotid endarterectomy. Concerns over in-stent restenosis, procedural complications, and stringent regulatory approval processes also pose barriers to growth. However, ongoing technological innovations, increasing investment in healthcare infrastructure, a growing elderly population at higher risk of stroke, and supportive government initiatives to enhance access to advanced vascular interventions are expected to sustain market momentum through 2032.
Market Trends
The market is witnessing a shift toward drug-eluting and bioabsorbable stents due to their ability to minimize in-stent restenosis and reduce long-term complications. These advanced stents improve vascular healing and patient outcomes, driving their preference over conventional bare-metal stents.
In June 2025, InspireMD, Inc., a developer of the CGuard Prime Carotid Stent System for the prevention of stroke, announced that the U.S. Food and Drug Administration (FDA) had granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the U.S.
The incorporation of AI-powered imaging, 3D mapping, and intravascular ultrasound (IVUS) is transforming carotid artery stenting procedures by enabling precise lesion assessment, optimized stent placement, and improved procedural safety. This trend is particularly prominent in developed healthcare markets.
According to a study published in June 2022 titled “Prediction of Carotid In-Stent Restenosis by Computed Tomography Angiography Carotid Plaque-Based Radiomics”, researchers analyzed 221 patients who underwent pre-CAS CTA (computed tomography angiography) and follow-up angiography to develop predictive models for in-stent restenosis after carotid artery stenting. The radiomics-based model demonstrated strong predictive performance, achieving an AUC of approximately 0.87 in the training cohort and 0.82 in the validation cohort. Furthermore, integrating radiomics features with conventional plaque characteristics enhanced the model’s predictive accuracy compared with either approach alone.
Market Opportunities
Many developing countries, especially in Asia Pacific, Latin America, and parts of Africa, have relatively low penetration of advanced stent technologies due to infrastructure, affordability, and awareness constraints. There’s an opportunity for manufacturers to introduce more cost-efficient carotid stent systems, partner with local healthcare providers, and support training programs. By doing so, companies can tap into large, unmet patient populations as healthcare access improves and stroke prevention becomes a priority.
In December 2024, an article published on the National Library of Medicine titled “Procedural and Short-Term Outcomes of Carotid Artery Stenting: A Single-Center Experience” reported that a single-center study in India, involving 39 patients who underwent carotid artery stenting between January 2022 and December 2023, evaluated procedural and short-term outcomes in patients with symptomatic carotid stenosis. The study indicates that carotid stenting is being increasingly performed in Indian tertiary centres, contributing to greater awareness and enhanced procedural capabilities in the region.
While bioabsorbable stents for carotid applications remain mostly in early stages, there’s growing clinical demand for solutions that reduce long-term complications like chronic inflammation and in-stent restenosis. Hybrid stents (e.g., combining temporary scaffold with drug elution) or bioabsorbables that degrade once vessel healing is adequate represent a promising R&D opportunity. Regulatory pathways are challenging, but first-mover advantage and clinical differentiation could drive strong uptake.
As per an article published in August 2025 titled “Preclinical Assessment of a Novel Polymer-Free Hybrid Drug-Eluting Stent”, a preclinical study evaluated a novel polymer-free hybrid drug-eluting stent (DES). This device is designed to combine the benefits of drug elution with a biodegradable scaffold, providing temporary vascular support that gradually degrades once vessel healing is complete. The study assessed its performance relative to benchmark devices and specific controls, addressing concerns related to long-term complications associated with conventional stents.
Analyst View
Recent Key Developments
Competitive Landscape
Carotid Artery Stent Market Segmentation
Regional Insights
Related Reports :